Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro

Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro

Abstract Background Prothrombin complex concentrate (PCC) is a human plasma‐derived mixture of partially purified vitamin K‐dependent coagulation factors (VKCF). Current therapeutic indication is treatment and perioperative prophylaxis of bleeding in acquired VKCF deficiency. Off‐label uses include...

Full description

Bibliographic Details
Main Authors: Herm Jan M. Brinkman, Frauke Swieringa, Marleen Zuurveld, Alicia Veninga, Sanne L. N. Brouns, Johan W. M. Heemskerk, Joost C. M. Meijers
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anticoagulants
dabigatran
factor V
prothrombin complex concentrate
rivaroxaban
Online Access:https://doi.org/10.1002/rth2.12699

Internet

https://doi.org/10.1002/rth2.12699

Similar Items